Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140851 | 0.93 | TRPV4 (0.48) | TRPV4MAPTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL13872605 | 0.93 | BMP1 (0.46) | TRPV4GAAMAPTLMNAALDH1A1 | |
| SCHEMBL4127510 | 0.92 | TRPV4 (0.47) | TRPV4GAAMAPTSMN1; SMN2LMNA | |
| SCHEMBL4135455 | 0.89 | TRPV4 (0.50) | TRPV4MAPTLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL4136473 | 0.88 | HTT (0.47) | TRPV4GAAMAPTSMN1; SMN2LMNA | |
| SCHEMBL4139657 | 0.80 | CAPN1 (0.51) | TRPV4GAAMAPTALDH1A1CAPN1 | |
| SCHEMBL4135576 | 0.78 | TP53 (0.43) | TRPV4GAAMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL4147709 | 0.77 | TRPV4 (0.44) | TRPV4CAPN1 | |
| SCHEMBL4139857 | 0.76 | TRPV4 (0.55) | TRPV4 | |
| SCHEMBL4127488 | 0.76 | TRPV4 (0.76) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | TRPV4 1/4885GAA 3715/4885MAPT 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.